Akebia Therapeutics, Inc. (AKBA) Stock Rating Reaffirmed by Mizuho
Mizuho reissued their buy rating on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in a report published on Thursday. The brokerage currently has a $24.00 price objective on the biopharmaceutical company’s stock.
AKBA has been the topic of a number of other research reports. Royal Bank Of Canada reiterated a hold rating and set a $17.00 target price on shares of Akebia Therapeutics in a report on Thursday, November 2nd. Zacks Investment Research upgraded Akebia Therapeutics from a hold rating to a buy rating and set a $16.00 target price on the stock in a report on Monday, August 14th. HC Wainwright reiterated a buy rating and set a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, August 9th. BidaskClub downgraded Akebia Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $20.63.
Akebia Therapeutics (AKBA) traded up $0.39 on Thursday, reaching $15.49. The company’s stock had a trading volume of 674,900 shares, compared to its average volume of 515,651. Akebia Therapeutics has a fifty-two week low of $7.78 and a fifty-two week high of $20.25.
Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. The firm had revenue of $41.28 million for the quarter, compared to the consensus estimate of $34.00 million. equities research analysts forecast that Akebia Therapeutics will post -2.74 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/akebia-therapeutics-inc-akba-stock-rating-reaffirmed-by-mizuho.html.
In related news, SVP Michel Dahan sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.30, for a total value of $96,500.00. Following the sale, the senior vice president now owns 97,224 shares in the company, valued at approximately $1,876,423.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 12,586 shares of company stock worth $222,289 in the last 90 days. 8.67% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Akebia Therapeutics in the 2nd quarter worth approximately $132,000. Legal & General Group Plc boosted its stake in Akebia Therapeutics by 8.0% during the 2nd quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the last quarter. Creative Planning boosted its stake in Akebia Therapeutics by 2.9% during the 2nd quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Akebia Therapeutics during the 2nd quarter valued at $159,000. Finally, Macquarie Group Ltd. purchased a new stake in Akebia Therapeutics during the 3rd quarter valued at $183,000. Institutional investors own 59.27% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.